Firefly Neuroscience Unveils AI-Powered Biomarker Discovery for PTSD

Firefly Neuroscience announced on June 2, 2026, the launch of an artificial intelligence-driven platform designed to identify biomarkers for post-traumatic stress disorder, aiming to improve diagnostic precision and accelerate treatment development. The company said the technology analyzes brain data to detect objective biological signals, reducing reliance on subjective patient assessments. The initiative targets a disorder affecting millions globally, where current diagnosis often depends on clinical interviews. By isolating specific neural patterns, the approach could enable earlier intervention and more personalized therapies. Firefly Neuroscience did not disclose financial terms or potential partners for the project. The announcement signals growing industry interest in applying AI to mental health, a field that has historically lagged in objective diagnostic tools.